Latest Germany News

Little Green Pharma has terminated its planned sale and leaseback of its Western Australian production facility after failing to reach commercial terms, choosing to retain ownership without impacting operations.

Vulcan Energy has obtained its inaugural lithium production licence for the Lionheart Project in Germany, marking a pivotal step as the project moves into funded construction. This licence supports Vulcan’s ambition to supply Europe with sustainable lithium for electric vehicle batteries, backed by renewable energy co-production.

Evion Group is advancing the Stage 2 expansion of its expandable graphite facility in India to boost production capacity amid rising demand from Europe, the USA, and Asia. The upgrade aligns with the EU’s recognition of graphite as a critical mineral, positioning Evion as a key supplier in strategic sectors.

Collins Foods is rapidly expanding its footprint in Germany through the acquisition of eight KFC restaurants in Bavaria and an ambitious development plan targeting up to 90 new outlets. Meanwhile, the company refocuses its Netherlands operations with a revamped franchise agreement.

South Harz Potash Limited has raised A$1.25 million to fund exploration at its newly licensed copper-gold projects in Sweden, signalling a strategic pivot towards critical minerals and a planned rebrand to Turnstone Resources.

Nanoveu’s subsidiary EMASS has unveiled a breakthrough reference design that integrates inertial sensing with edge AI to enable always-on, ultra-low-power voice interaction in hearable devices. This innovation promises to extend battery life while delivering real-time, hands-free voice control without cloud reliance.

Control Bionics has secured a key regulatory milestone with its NeuroNode device now eligible for reimbursement under Germany’s statutory health insurance, paving the way for expanded European distribution.

Neuren Pharmaceuticals’ partner Acadia Pharmaceuticals is seeking a re-examination of the European Medicines Agency’s refusal to approve trofinetide for Rett syndrome, aiming to overturn the setback and bring the treatment to European patients.

Bioxyne Limited has reported a remarkable half-year performance, with revenues soaring 149% to $31.3 million and net profit more than doubling to $7.3 million, driven by strong demand for medicinal cannabis, MDMA, and psilocybin products and expanding international operations.

Cyclopharm Limited reported a 17% revenue increase to a record $32.3 million in 2025, powered by a 226% surge in US Technegas sales. The company is accelerating its US rollout with plans for up to 300 installations in 2026, while advancing clinical trials beyond pulmonary embolism.

OncoSil Medical has reported record dose sales and cash receipts in the first half of FY26, supported by encouraging clinical trial results and expanded European market penetration.

PlaySide Studios reported a sharp 28% revenue decline for H1 FY26 but posted a remarkable 249% jump in profit, buoyed by cost cuts and a $7.8 million tax rebate. The company also secured a $6 million loan and inked a new global publishing deal.